May 2nd, 2011
FDA Approves New Drug for Type 2 Diabetes
Larry Husten, PHD
The FDA announced today that it has approved linagliptin, a new drug for type 2 diabetes. The DPP-4 inhibitor was developed by Eli Lilly and Boehringer Ingelheim and will be sold under the brand name of Tradjenta. Linagliptin was studied in 3,800 patients with type 2 diabetes, the FDA said, and was better than placebo […]
May 1st, 2011
Don’t Miss the New AHA Recommendations on Triglycerides
Harlan M. Krumholz, MD, SM
I’ve been surprised at the lack of fanfare surrounding the American Heart Association’s recently published scientific statement on triglycerides and cardiovascular disease (CVD). The attention it did receive focused on the lower fasting triglyceride level that is now considered optimal: <100 mg/dL. In my opinion, the real headline was the committee’s important statements in support of […]